RiDYMO® Designs Cyclic Peptide for "Undruggable" β-Catenin Target Within Two Months
In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting ...
TMCnet5d
RiDYMO® Designs Cyclic Peptide for "Undruggable" ß-Catenin Target Within Two Months
RiDYMO® has been successfully employed in various drug discovery programs, including the development of small molecule ...
Boehringer Ingelheim Acquires Fourth License for the Development of Novel Antibody Based Cancer Treatments from Oxford BioTherapeutics
Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of ...
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics ...
Scientists develop nanobody inhibitors to target deadly Ebola virus
Ebola virus, one of the deadliest pathogens, has a fatality rate of about 50%, posing a serious threat to global health and ...
Stoke Therapeutics’ Promising Potential: Buy Rating Backed by Strong Phase 3 Trial Design and Positive Early Results
Stoke Therapeutics (STOK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein ...
GEN6d
AI Accelerates and Expands Drug Development
By combining diverse datasets and powerful analytical and modeling tools, drug developers are finding more potential ...
Pharm Exec5d
Artificial Intelligence Makes Possible a Multiomic Approach in Oncology Drug Discovery
While challenges remain, AI is accelerating the process by enabling researchers to identify and design new drug candidates ...
C&EN2d
Deep Drug–Target Binding Affinity Prediction Base on Multiple Feature Extraction and Fusion
Predicting drug–target binding affinity (DTA ... our goal is to design efficient and accurate prediction methods that effectively handle the sequence information. Based on our observation, there are ...
News Medical on MSN4d
AI-designed drug shows promise for inflammatory bowel disease
Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announces positive results from two Phase I studies in ...